Could less immunotherapy be just as good for advanced nose cancer?

NCT ID NCT07373990

Not yet recruiting Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial will test whether a shorter course of the immunotherapy drug tislelizumab, combined with chemotherapy and radiation, works as well as a longer course for people with advanced nasopharyngeal cancer. About 418 participants will be randomly assigned to receive either 3 or 5 cycles of tislelizumab after initial treatment. The main goal is to see if the shorter course is non-inferior in preventing cancer from returning or spreading.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tislelizumab (an immunotherapy drug)
What this could lead to: If successful, this could show that a shorter course of immunotherapy is just as effective as a longer one, reducing treatment burden for patients with advanced nasopharyngeal cancer.
What could go wrong: This is a non-inferiority trial, so the shorter course might prove slightly less effective. The study is not yet recruiting, and results will take years. Immunotherapy can cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma nasopharyngeal carcinoma, susceptibility to, 1 nasopharyngeal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARYNGEAL CANCER NASOPHARYNGEAL CANCINOMA (NPC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.